Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix and ASU Center to Co-develop Peptide Synthesizer for Polypeptide Arrays

NEW YORK, Aug. 12 (GenomeWeb News) - CombiMatrix and the Biodesign Institute at Arizona State University plan to co-develop a peptide array synthesizer using CombiMatrix's virtual-flask technology, the partners said today.


Terms of the agreement call for the partners to develop a peptide synthesizer that can build polypeptide arrays on CombiMatrix CustomArrays platform. As part of the alliance, the Biodesign Institute's Center for BioOptical Nanotechnology will buy CombiMatrix equipment and pay for the development costs. CombiMatrix, for its part, will grant technology rights and contributing expertise.


CombiMatrix and the Institute will share revenue from any peptide array synthesizer, peptide array products, or intellectual property that might be developed.
The Arizona Technology Enterprises, the technology commercialization company for ASU and the Biodesign Institute, helped facilitate the deal. The Center for BioOptical Nanotechnology "will pursue rapid commercialization of these technologies," CombiMatrix said in a statement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.